Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan
Status:
Completed
Trial end date:
2016-08-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to assess the effects of subcutaneous sumatriptan
alone and the effects of a single dose of erenumab (AMG 334) intravenous (IV) and sumatriptan
concomitant therapy on resting blood pressure in healthy adults.